OBJECTIVE: In rheumatoid arthritis (RA) several recent efforts have sought to discover means of predicting which patients would benefit from treatment. However, results have been discrepant with few successful replications. Our objective was to build a biobank with DNA, RNA and protein measurements to test the claim that the current state-of-the-art precision medicine will benefit RA patients. METHODS: We collected 451 blood samples from 61 healthy individuals and 185 RA patients initiating treatment, before treatment initiation and at a 3 month follow-up time. All samples were subjected to high-throughput RNA sequencing, DNA genotyping, extensive proteomics and flow cytometry measurements, as well as comprehensive clinical phenotyping. Literature review identified 2 proteins, 52 single-nucleotide polymorphisms (SNPs) and 72 gene-expression biomarkers that had previously been proposed as predictors of TNF inhibitor response (∆DAS28-CRP). RESULTS: From these published TNFi biomarkers we found that 2 protein, 2 SNP and 8 mRNA biomarkers could be replicated in the 59 TNF initiating patients. Combining these replicated biomarkers into a single signature we found that we could explain 51% of the variation in ∆DAS28-CRP. This corresponds to a sensitivity of 0.73 and specificity of 0.78 for the prediction of three month ∆DAS28-CRP better than -1.2. CONCLUSIONS: The COMBINE biobank is currently the largest collection of multi-omics data from RA patients with high potential for discovery and replication. Taking advantage of this we surveyed the current state-of-the-art of drug-response stratification in RA, and identified a small set of previously published biomarkers available in peripheral blood which predicts clinical response to TNF blockade in this independent cohort.
OBJECTIVE: In rheumatoid arthritis (RA) several recent efforts have sought to discover means of predicting which patients would benefit from treatment. However, results have been discrepant with few successful replications. Our objective was to build a biobank with DNA, RNA and protein measurements to test the claim that the current state-of-the-art precision medicine will benefit RApatients. METHODS: We collected 451 blood samples from 61 healthy individuals and 185 RApatients initiating treatment, before treatment initiation and at a 3 month follow-up time. All samples were subjected to high-throughput RNA sequencing, DNA genotyping, extensive proteomics and flow cytometry measurements, as well as comprehensive clinical phenotyping. Literature review identified 2 proteins, 52 single-nucleotide polymorphisms (SNPs) and 72 gene-expression biomarkers that had previously been proposed as predictors of TNF inhibitor response (∆DAS28-CRP). RESULTS: From these published TNFi biomarkers we found that 2 protein, 2 SNP and 8 mRNA biomarkers could be replicated in the 59 TNF initiating patients. Combining these replicated biomarkers into a single signature we found that we could explain 51% of the variation in ∆DAS28-CRP. This corresponds to a sensitivity of 0.73 and specificity of 0.78 for the prediction of three month ∆DAS28-CRP better than -1.2. CONCLUSIONS: The COMBINE biobank is currently the largest collection of multi-omics data from RApatients with high potential for discovery and replication. Taking advantage of this we surveyed the current state-of-the-art of drug-response stratification in RA, and identified a small set of previously published biomarkers available in peripheral blood which predicts clinical response to TNF blockade in this independent cohort.
Entities:
Keywords:
TNF-alpha; biobank; drug response; pharmacogenetics; rheumatoid arthritis
Authors: Bo Sun; Hui-Hsin Chang; Ari Salinger; Beverly Tomita; Mandar Bawadekar; Caitlyn L Holmes; Miriam A Shelef; Eranthie Weerapana; Paul R Thompson; I-Cheng Ho Journal: JCI Insight Date: 2019-11-14
Authors: Hui-Hsin Chang; Ching-Huang Ho; Beverly Tomita; Andrea A Silva; Jeffrey A Sparks; Elizabeth W Karlson; Deepak A Rao; Yvonne C Lee; I-Cheng Ho Journal: J Autoimmun Date: 2019-04-26 Impact factor: 7.094
Authors: Yolima Puentes-Osorio; Pedro Amariles; Miguel Ángel Calleja; Vicente Merino; Juan Camilo Díaz-Coronado; Daniel Taborda Journal: Auto Immun Highlights Date: 2021-05-31
Authors: Klementy Shchetynsky; Lina-Marcella Diaz-Gallo; Lasse Folkersen; Aase Haj Hensvold; Anca Irinel Catrina; Louise Berg; Lars Klareskog; Leonid Padyukov Journal: Arthritis Res Ther Date: 2017-02-02 Impact factor: 5.156
Authors: Jonas Bystrom; Felix I Clanchy; Taher E Taher; Mohammed M Al-Bogami; Hawzheen A Muhammad; Saba Alzabin; Pamela Mangat; Ali S Jawad; Richard O Williams; Rizgar A Mageed Journal: Clin Rev Allergy Immunol Date: 2017-10 Impact factor: 8.667
Authors: C Derambure; G Dzangue-Tchoupou; C Berard; N Vergne; M Hiron; M A D'Agostino; P Musette; O Vittecoq; T Lequerré Journal: Arthritis Res Ther Date: 2017-05-25 Impact factor: 5.156